Evidence map›Paper›PMID 34305915›Full record

ReviewFrontiers in immunology2021

Immune Myocarditis Overlapping With Myasthenia Gravis Due to Anti-PD-1 Treatment for a Chordoma Patient: A Case Report and Literature Review.

Shujing Liang, Jingxian Yang, Yun Lin, Tong Li, Wenrong Zhao, Jun Zhao, Chunyan Dong

Open access · goldAbstract readCase ReportsReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 3 pooled it
2.0field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 3 syntheses or guidelines pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Immune Checkpoint Inhibitors Related to Cardiotoxicity.Journal of cardiovascular development and disease · 2022
    Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Shujing LiangDepartment of Oncology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Jingxian YangDepartment of Oncology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Yun LinDepartment of Oncology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Tong LiDepartment of Oncology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Wenrong ZhaoDepartment of Oncology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Jun ZhaoDepartment of Nuclear Medicine, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Chunyan DongDepartment of Oncology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Shanghai East Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunotherapy begins to be widely used due to the increasing exploration and gratifying effects in multiple cancers. Chordoma, as a rare bone malignant tumor, often recurs and metastasizes after undergoing surgery and radiotherapy. Therefore, immunotherapy can be explored as an emerging, potentially effective treatment to improve the survival rate and clinical benefit of patients. However, a variety of immune-related adverse events (irAEs) cannot be avoided completely. And the immunotherapy-induced myocarditis, as a rare but fatal irAE, has been increasingly reported. Understanding the mechanism involved in irAEs can inform best practices for side effects management. Here, we firstly reported a case of immune myocarditis and subsequent myasthenia gravis (MG) following anti-PD-1 treatment for chordoma.

Indexed as

AgedAntineoplastic Agents, ImmunologicalBiomarkersChordomaHeart Function TestsHumansImmunosuppressive AgentsKidney Function TestsLiver Function TestsMagnetic Resonance ImagingMaleMolecular Targeted TherapyMyasthenia GravisMyocarditisPositron-Emission TomographyProgrammed Cell Death 1 ReceptorAntineoplastic Agents, ImmunologicalBiomarkersImmunosuppressive AgentsPDCD1 protein, humanProgrammed Cell Death 1 Receptorchordomaimmune checkpoint inhibitormyasthenia gravismyocarditisPD-1 blockadesintilimab

Identifiers

PMID34305915
PMCPMC8297709
OpenAlexW3180810155

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.